Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers

This article was originally published in The Tan Sheet

Executive Summary

Between five and 10 product liability companies have stopped offering coverage for ephedra alkaloid-containing products since June, when HHS Secretary Tommy Thompson issued a statement on ephedra's safety
Advertisement

Related Content

Twinlab Faces Sale, Chapter 11 As Debt Looms
Twinlab Faces Sale, Chapter 11 As Debt Looms
Twinlab Faces Sale, Chapter 11 As Debt Looms
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Herbal Regulatory Category Creation At FDA Suggested By Sen. Durbin
HHS/FDA Ephedra Strategy: A Risk Management Approach?
HHS/FDA Ephedra Strategy: A Risk Management Approach?
Nebraska ephedrine law exempts new Primatene Tablets, Bronkaid Dual Action.

Topics

Advertisement
UsernamePublicRestriction

Register

PS094503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel